The 14 Billion Dose COVID-19 Manufacturing Challenge
mRNA Vaccines Leading The Way
Executive Summary
Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.
You may also be interested in...
Pfizer Rose To The COVID-19 Challenge And The Stars Aligned
Pfizer moved aggressively and early as COVID-19 became a global health threat, and now the company, with its partner BioNTech, is the first to secure an emergency use authorization for a COVID vaccine from the US FDA.
AZ And J&J’s Problems Fuel Demand For Pfizer and Moderna COVID-19 Vaccines
Pfizer/BioNTech is emerging as the EU’s partner of choice for COVID-19 vaccines, but others could also benefit.
CureVac Could Be Third mRNA Vaccine Approval – But With A ‘Europe First’ Approach
Caught in a ‘vaccine nationalism’ crossfire a year ago, CureVac is now well placed to become a commercial entity – just as long as its mRNA platform can deliver.